Establishment Labs (ESTA) Q2 2026 earnings review
U.S. Hypergrowth Masks International Stagnation
Establishment Labs delivered a powerful headline quarter, highlighted by a 31.7% YoY surge in total revenue and an upward revision to full-year guidance ($269M-$271M). The growth engine is almost entirely the United States, where Motiva sales skyrocketed 140% YoY to $24.7M, marking a clear accelerating trend. Operating leverage is finally materializing, with Adjusted EBITDA reaching a positive $3.7M. However, investors must look below the surface: the core international business is severely decelerating, growing a mere 4.4% YoY. Furthermore, the company's hefty debt load generated $7.0M in interest expense, keeping GAAP Net Income deep in the red (-$11.7M). This is a tale of two companies: a booming, premium U.S. startup attached to a stagnant legacy global business.
🐂 Bull Case
The Motiva U.S. launch continues to crush expectations. Sequential growth of 26% in Q2 proves the product is taking real share from entrenched incumbents, driven by high safety profiles and patient pull-through.
Gross margins have expanded steadily from 68.8% a year ago to 70.6% today. The mix shift toward premium U.S. pricing and minimally invasive platforms is structurally elevating profitability.
🐻 Bear Case
The company boasts about positive Adjusted EBITDA ($3.7M), but this excludes a crippling $7.0M quarterly interest expense resulting from recent refinancing. The path to true GAAP cash flow remains obstructed by the balance sheet.
Stripping out the U.S., the rest of the world (OUS) generated $42.8M, up just 4.4% from $41.0M in 25Q2. Macroeconomic headwinds and distributor issues in regions like China are dragging down the legacy business.
⚖️ Verdict: ⚪
Cautiously Bullish. The U.S. market momentum and the premium minimally invasive platform are spectacular drivers. However, reliance on non-GAAP metrics while interest expenses devour cash flow limits conviction.
Key Themes
U.S. Adoption is Accelerating Rapidly
The U.S. market is ESTA's primary growth engine, accelerating from $10.3M in 25Q2 to $24.7M in 26Q2. This represents 140% YoY growth and now accounts for nearly 37% of total company revenue. Management is successfully leveraging direct-to-consumer marketing and clinical safety data to generate patient-led demand that bypasses traditional surgeon-led choice.
Minimally Invasive Platform (Preservé/Mia) Elevates ASPs
The minimally invasive platform generated $12.1M in Q2. Because these procedures command premium pricing (often up to 2x a traditional augmentation), this segment is a dual catalyst: it brings new, previously hesitant patients into the TAM and directly drives the gross margin expansion to 70.6%.
International Growth is Decelerating and Stagnant
While the U.S. launch dominates the narrative, the OUS (Outside U.S.) segment is severely lagging. OUS revenue grew only 4.4% YoY ($42.8M vs $41.0M). This confirms previous management warnings about weakness in distributor markets like China and global macroeconomic sluggishness. This extreme divergence makes the company entirely dependent on a single geography for its growth story.
Operating Leverage is Demonstrable
ESTA is finally achieving scale. Total operating expenses in Q2 were $52.0M. Excluding $2.2M in one-time refinancing and restructuring charges, adjusted operating expenses grew a mere 2.0% YoY, while top-line revenue surged 31.7%. This disciplined cost control allowed Adjusted EBITDA to expand by $12.2M YoY to $3.7M.
Interest Expenses Devour Operating Gains
The company's Oaktree debt facility is a massive drag on actual cash generation. Interest expense in Q2 was $7.0M (up 18% YoY). So while management celebrates $3.7M in Adjusted EBITDA, the company still posted an $11.7M net loss. Debt refinancing costs and restructuring charges ($2.2M) further muddy the waters. ESTA is operating leverage positive, but balance sheet negative.
Other KPIs
Stable. Up from 68.8% in the year-ago period and roughly flat sequentially vs 26Q1 (70.7%). The mix shift toward the U.S. and the minimally invasive platform is structurally supporting this higher tier of profitability.
Stable. Up slightly sequentially from $68.1M in Q1, but down from $75.6M at the end of FY25. Management states there is no need for further equity financing, but with heavy quarterly interest payments, the cash runway relies heavily on H2 revenue accelerating to reach promised free cash flow positivity.
Guidance
Accelerating. Raised from previous guidance of $266.5M - $268.5M. The new midpoint ($270M) implies roughly 28% YoY growth over FY25's ~$211M. Given H1 2026 revenue was $127.4M, the guidance implies a strong acceleration in H2 to ~$142.6M, which will demand continued hypergrowth from the U.S. segment.
Key Questions
International Stagnation
Excluding the U.S., revenue grew less than 5% this quarter. Is this purely macroeconomic, or are there structural issues with OUS distributors losing share to local competitors?
Bridge to GAAP Profitability
You highlight Adjusted EBITDA positivity, but interest expense alone is $7M a quarter. At what U.S. revenue run-rate do you expect GAAP net income to turn positive?
Silicone Cost Risks
With the Nusil long-term supply agreement still under negotiation for 2027 and beyond, how exposed are gross margins to potential price hikes in your core raw materials?